Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management

Fineline Cube Jul 6, 2026
Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Fineline Cube Jul 6, 2026
Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Fineline Cube Jul 6, 2026
Company Drug

Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Approval for NSCLC Perioperative Treatment

Fineline Cube Jan 3, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company Drug

Roche’s Phesgo and Faricimab Receive NMPA Approvals for Breast Cancer and nAM

Fineline Cube Jan 3, 2024

The National Medical Products Administration (NMPA) has granted separate approvals for two distinct drugs from...

Company Deals

WuXi XDC and IntoCell Enter MOU to Advance Toxin Linker Technology and CRDMO Services

Fineline Cube Jan 3, 2024

WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...

Company Drug

BeiGene’s Tislelizumab Secures 12th Indication Approval in China for HCC First-Line Treatment

Fineline Cube Jan 3, 2024

BeiGene (NASDAQ: BGNE) has announced that its programmed death-1 (PD-1) inhibitor, tislelizumab, has received approval...

Company Drug

BMS’ Augtyro Receives EMA Review for Advanced Lung Cancer and Solid Tumors Treatments

Fineline Cube Jan 3, 2024

The European Medicines Agency (EMA) has accepted for review a filing submitted by Bristol Myers...

Company Deals

Allorion Therapeutics Strikes Deal with AstraZeneca for EGFR L858R Inhibitor Development and Commercialization

Fineline Cube Jan 3, 2024

Allorion Therapeutics, a China-based biopharmaceutical company, has announced an exclusive option and global licensing agreement...

Company Deals

Orient Gene Biotech to Acquire Hangzhou Laihe Biotech, Expanding POCT and AI in Healthcare

Fineline Cube Jan 3, 2024

Zhejiang Orient Gene Biotech Co., Ltd, a leading biotech company in China, is poised to...

Company Deals

Shanghai Teogen Life Technology and China National Medical Device Form Strategic Partnership

Fineline Cube Jan 3, 2024

Shanghai Teogen Life Technology Co., Ltd, a Chinese-based company, has announced a strategic partnership with...

Company Deals

Shanghai Pharmaceuticals and Sanofi Broaden Collaboration to Include Nationwide Disease Management

Fineline Cube Jan 3, 2024

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) , a leading pharmaceutical company based in China,...

Company Legal / IP

Servier Faces $475 Million Penalty Over Banned Antidiabetic Drug Mediator in France

Fineline Cube Jan 2, 2024

French pharmaceutical company Servier has been ordered by a French court to pay €430.6 million...

Company Legal / IP

J&J Shareholders Cleared to Sue Over Hidden Asbestos Risks in Talc Products

Fineline Cube Jan 2, 2024

A US federal court has granted permission for certain Johnson & Johnson (J&J; NYSE: JNJ)...

Policy / Regulatory

China’s CDE Releases Guidelines for CGT Clinical Trials Communication

Fineline Cube Jan 2, 2024

The Center for Drug Evaluation (CDE) in China has released the “Technical Guiding Principles for...

Policy / Regulatory

China’s NHC Unveils Plan to Conserve Drug Resources and Reduce Waste

Fineline Cube Jan 2, 2024

The National Health Commission (NHC) of China, in collaboration with four other bureaus, has released...

Policy / Regulatory

China’s NHC Unveils Guidelines to Fortify County-Level Medical Communities

Fineline Cube Jan 2, 2024

The National Health Commission (NHC) of China, in conjunction with nine other ministries, has issued...

Company Deals

Roche to Expand Diagnostics Portfolio with Acquisition of LumiraDx Technology

Fineline Cube Jan 2, 2024

Pharmaceutical giant Roche (SWX: ROG), based in Switzerland, has announced an agreement to acquire innovative...

Company Drug

Huadong Medicine Ends Collaboration on vTv’s TTP273 for Diabetes Treatment

Fineline Cube Jan 2, 2024

US-based vTv Therapeutics LLC has received a cancellation notice from China’s Huadong Medicine Co., Ltd.,...

Company Deals

Roche Secures Diagnostics Deal with LumiraDx for $295M

Fineline Cube Jan 2, 2024

Switzerland’s pharmaceutical giant Roche (SWX: ROG) has sealed a deal to acquire innovative diagnostics technology...

Company Deals

Huadong Medicine Cancels Collaboration with vTv Therapeutics on TTP273 for Type 2 Diabetes Drug

Fineline Cube Jan 2, 2024

vTv Therapeutics LLC, a US-based pharmaceutical company, has announced receiving a cancellation notification from China-based...

Company Drug

Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study

Fineline Cube Jan 2, 2024

Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results...

Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in Obesity Treatment

Fineline Cube Jan 2, 2024

Innovent Biologics Inc., a biopharmaceutical company based in China (HKG: 1801), has announced the first...

Posts pagination

1 … 446 447 448 … 690

Recent updates

  • Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic
  • Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment
  • China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways
  • Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment
  • Hua Medicine Partners with GemVCare on Real-World Clinical Study for Dorzagliatin in Precision Diabetes Management
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sino Biopharmaceutical Submits China Marketing Application for World’s First Intra-Incisional Long-Acting Ropivacaine Analgesic

Company Drug

Shaanxi Micot Enrolls First Patient in Phase Ib/II Clinical Trial of MT1002 for Acute Ischemic Stroke Treatment

Others

China’s NMPA Unveils Comprehensive Regulatory Framework for Cell and Gene Therapy Products with Streamlined Review Pathways

Company Drug

Changchun High & New Tech Secures NMPA Clinical Approval for GenSci164 PTH1R Agonist in Hypoparathyroidism Treatment

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.